12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amuvatinib: Development discontinued

Astex discontinued development of amuvatinib after data from 21 evaluable SCLC patients in stage 1 of the open-label, 2-stage, U.S. and Polish Phase II ESCAPE trial showed that the compound missed the pre-specified stage 1 primary response rate endpoint. Specifically, the endpoint required excluding the statistical probability with 90% confidence that amuvatinib had less than...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >